GSK, Chroma in potential $1B deal over anti-inflammatory drugs

06/23/2009 | Reuters

GlaxoSmithKline is teaming up with Chroma Therapeutics to secure rights to the latter's small-molecule compounds that target macrophages to treat inflammatory diseases such as rheumatoid arthritis. Chroma could receive more than $1 billion out of the deal depending on the success of the four drug programs, which employ its proprietary esterase-sensitive motif technology to enhance drug delivery.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD